Taysha Gene Therapies, Inc.
TSHA Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$3.96
1.1%
Revenue
Total sales reported in the income statement.
$9.8M
17.3%
vs prior year
Operating margin
Operating income as a share of revenue.
โ1,130.6%
33.1ย pts
Net income
Profit after all expenses, interest and tax.
โ$109M
Free cash flow
Cash from operations minus capital spending.
โ$93.8M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.5B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$0.42 EPS (TTM)
What Taysha Gene Therapies, Inc. does
No business description yet.
- Legal name
- Taysha Gene Therapies, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 19, 2026
- Accession ยท CIK
- 0001193125-26-115202
0001806310
Revenue and margins
Taysha Gene Therapies, Inc. had $9.8M of revenue in fiscal 2025, up 17.3% on the year before.
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue $2.5M
FY23
Revenue $15.5M
FY24
Revenue $8.3M
FY25
Revenue $9.8M
Q3 '23
Revenue $4.7M
Q4 '23
Revenue $3.6M
Q1 '24
Revenue $3.4M
Q2 '24
Revenue $1.1M
Q3 '24
Revenue $1.8M
Q4 '24
Revenue $2.0M
Q1 '25
Revenue $2.3M
Q2 '25
Revenue $2.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $5.5M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ6,492.7%
Net โ6,635.3%
FCF โ4,356.9%
FY23
Gross โ
Operating โ468.8%
Net โ722.1%
FCF โ497.6%
FY24
Gross โ
Operating โ1,097.6%
Net โ1,071.6%
FCF โ979.2%
FY25
Gross โ
Operating โ1,130.6%
Net โ1,115.3%
FCF โ960.1%
Gross
Operating
Net
FCF
Q3 '23
Gross โ
Operating โ342.4%
Net โ2,467.1%
FCF โ378.2%
Q4 '23
Gross โ
Operating โ450.8%
Net 1,324.7%
FCF โ447.7%
Q1 '24
Gross โ
Operating โ713.3%
Net โ705.4%
FCF โ584.5%
Q2 '24
Gross โ
Operating โ1,915.4%
Net โ1,882.0%
FCF โ1,951.9%
Q3 '24
Gross โ
Operating โ1,448.4%
Net โ1,427.5%
FCF โ1,210.9%
Q4 '24
Gross โ
Operating โ985.8%
Net โ929.0%
FCF โ905.3%
Q1 '25
Gross โ
Operating โ930.5%
Net โ935.2%
FCF โ973.0%
Q2 '25
Gross โ
Operating โ1,347.1%
Net โ1,353.6%
FCF โ1,016.3%
Q3 '25
Gross โ
Operating โ
Net โ
FCF โ
Q4 '25
Gross โ
Operating โ516.0%
Net โ507.8%
FCF โ491.7%
Q1 '26
Gross โ
Operating โ
Net โ
FCF โ
Q2 '26
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$60.0M
FY21
Net income โ$175M
FY22
Net income โ$166M
FY23
Net income โ$112M
FY24
Net income โ$89.3M
FY25
Net income โ$109M
Q3 '23
Net income โ$117M
Q4 '23
Net income $47.7M
Q1 '24
Net income โ$24.1M
Q2 '24
Net income โ$20.9M
Q3 '24
Net income โ$25.5M
Q4 '24
Net income โ$18.8M
Q1 '25
Net income โ$21.5M
Q2 '25
Net income โ$26.9M
Q3 '25
Net income โ$32.7M
Q4 '25
Net income โ$27.9M
Q1 '26
Net income โ$42.4M
Q2 '26
Net income โ$46.6M
FY20
Diluted EPS โ$3.40
FY21
Diluted EPS โ$4.64
FY22
Diluted EPS โ$3.78
FY23
Diluted EPS โ$0.96
FY24
Diluted EPS โ$0.36
FY25
Diluted EPS โ$0.34
Q3 '23
Diluted EPS โ$0.93
Q4 '23
Diluted EPS $0.63
Q1 '24
Diluted EPS โ$0.10
Q2 '24
Diluted EPS โ$0.09
Q3 '24
Diluted EPS โ$0.10
Q4 '24
Diluted EPS โ$0.07
Q1 '25
Diluted EPS โ$0.08
Q2 '25
Diluted EPS โ$0.09
Q3 '25
Diluted EPS โ$0.09
Q4 '25
Diluted EPS โ$0.08
Q1 '26
Diluted EPS โ$0.12
Q2 '26
Diluted EPS โ$0.13
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ23.9%
Return on assets โ23.2%
FY21
Return on capital โ
Return on equity โ100.7%
Return on assets โ73.8%
FY22
Return on capital โ
Return on equity โ344.7%
Return on assets โ97.6%
FY23
Return on capital โ
Return on equity โ294.0%
Return on assets โ74.6%
FY24
Return on capital โ
Return on equity โ121.9%
Return on assets โ53.6%
FY25
Return on capital โ
Return on equity โ68.5%
Return on assets โ43.3%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$93.8M in fiscal 2025, โ960.1% of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$30.8M
FY21
Free cash flow โ$132M
FY22
Free cash flow โ$109M
FY23
Free cash flow โ$76.9M
FY24
Free cash flow โ$81.6M
FY25
Free cash flow โ$93.8M
Q3 '23
Free cash flow โ$17.9M
Q4 '23
Free cash flow โ$16.1M
Q1 '24
Free cash flow โ$19.9M
Q2 '24
Free cash flow โ$21.7M
Q3 '24
Free cash flow โ$21.7M
Q4 '24
Free cash flow โ$18.3M
Q1 '25
Free cash flow โ$22.4M
Q2 '25
Free cash flow โ$20.2M
Q3 '25
Free cash flow โ$24.3M
Q4 '25
Free cash flow โ$27.0M
Q1 '26
Free cash flow โ$40.9M
Q2 '26
Free cash flow โ$40.4M
FY20
Cash from operations โ$30.7M
Capital spending $0.1M
FY21
Cash from operations โ$117M
Capital spending $15.3M
FY22
Cash from operations โ$88.4M
Capital spending $20.6M
FY23
Cash from operations โ$73.0M
Capital spending $3.9M
FY24
Cash from operations โ$81.2M
Capital spending $0.4M
FY25
Cash from operations โ$93.1M
Capital spending $0.7M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$17.9M
Capital spending $0.0M
Q4 '23
Cash from operations โ$16.1M
Capital spending $0.0M
Q1 '24
Cash from operations โ$19.8M
Capital spending $0.1M
Q2 '24
Cash from operations โ$21.5M
Capital spending $0.2M
Q3 '24
Cash from operations โ$21.6M
Capital spending $0.0M
Q4 '24
Cash from operations โ$18.3M
Capital spending โ$0.0M
Q1 '25
Cash from operations โ$22.0M
Capital spending $0.4M
Q2 '25
Cash from operations โ$20.2M
Capital spending $0.0M
Q3 '25
Cash from operations โ$24.2M
Capital spending $0.1M
Q4 '25
Cash from operations โ$26.7M
Capital spending $0.3M
Q1 '26
Cash from operations โ$40.9M
Capital spending $0.0M
Q2 '26
Cash from operations โ$40.4M
Capital spending โ$0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Taysha Gene Therapies, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 27.8%.
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.02B
FY21
Diluted shares 0.04B
FY22
Diluted shares 0.04B
FY23
Diluted shares 0.12B
FY24
Diluted shares 0.25B
FY25
Diluted shares 0.32B
Balance sheet
Cash, debt and the ratios that show how comfortably Taysha Gene Therapies, Inc. can carry it.
FY20
Cash $251M
Debt โ
FY21
Cash $149M
Debt $37.2M
FY22
Cash $87.9M
Debt $39.4M
FY23
Cash $144M
Debt $41.6M
FY24
Cash $139M
Debt $44.7M
FY25
Cash $320M
Debt $50.5M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $149M | $87.9M | $144M | $139M | $320M |
| Debt incl. finance leases | $37.2M | $39.4M | $41.6M | $44.7M | $50.5M |
| Debt / equity | 0.4x | 40.0x | 0.5x | 0.6x | 0.2x |
| Interest coverage | โ121.3x | โ42.8x | โ14.5x | โ896.7x | โ1,753.9x |
| Current ratio | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Quick ratio | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Total assets | $214M | $126M | $173M | $160M | $343M |
| Total liabilities | $119M | $125M | $97.8M | $88.8M | $96.4M |
| Shareholders' equity | $95.4M | $0.9M | $74.9M | $71.5M | $247M |
| Net debt (โ = net cash) | โ$112M | โ$48.5M | โ$102M | โ$94.3M | โ$269M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | 1 / 7 | 5 / 8 | 3 / 8 | 4 / 8 |
| Accruals ratio | โ11.3% | โ24.3% | โ45.6% | โ25.8% | โ4.8% | โ6.3% |
| Altman Z'' | 39.28 | โ4.88 | โ17.25 | โ7.40 | โ10.49 | โ0.53 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | โ | โ | $2.5M | $15.5M | $8.3M | $9.8M |
| Research and development | $31.9M | $132M | $91.2M | $56.8M | $66.0M | $86.4M |
| Operating income | โ$43.0M | โ$173M | โ$162M | โ$72.4M | โ$91.5M | โ$110M |
| Interest expense | $0.0M | $1.4M | $3.8M | $5.0M | $0.1M | $0.1M |
| Income tax | $0.0M | โ | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$60.0M | โ$175M | โ$166M | โ$112M | โ$89.3M | โ$109M |
| Net income to common | โ$60.0M | โ$175M | โ$166M | โ$112M | โ$89.3M | โ$109M |
| Diluted EPS | โ$3.40 | โ$4.64 | โ$3.78 | โ$0.96 | โ$0.36 | โ$0.34 |
| Diluted shares | 0.02B | 0.04B | 0.04B | 0.12B | 0.25B | 0.32B |
| Cash flow | ||||||
| Cash from operations | โ$30.7M | โ$117M | โ$88.4M | โ$73.0M | โ$81.2M | โ$93.1M |
| Capital expenditure | $0.1M | $15.3M | $20.6M | $3.9M | $0.4M | $0.7M |
| Free cash flow | โ$30.8M | โ$132M | โ$109M | โ$76.9M | โ$81.6M | โ$93.8M |
| Depreciation and amortization | $0.0M | $0.5M | $1.2M | $1.4M | $1.2M | $1.1M |
| Stock-based compensation | $3.4M | $18.2M | $18.0M | $7.9M | $13.1M | $13.3M |
| Balance sheet | ||||||
| Cash and short-term investments | $251M | $149M | $87.9M | $144M | $139M | $320M |
| Total debt | โ | $37.2M | $38.0M | $40.5M | $43.9M | $50.1M |
| Finance lease liabilities | โ | โ | $1.5M | $1.1M | $0.8M | $0.4M |
| Current assets | $258M | $160M | $96.4M | $150M | $142M | $325M |
| Current liabilities | $7.1M | $51.7M | $62.8M | $36.8M | $26.2M | $26.6M |
| Property and equipment, net | $0.3M | $50.6M | $15.0M | $10.8M | $7.5M | $6.7M |
| Total assets | $259M | $214M | $126M | $173M | $160M | $343M |
| Total liabilities | $7.6M | $119M | $125M | $97.8M | $88.8M | $96.4M |
| Shareholders' equity | $251M | $95.4M | $0.9M | $74.9M | $71.5M | $247M |
| Margins | ||||||
| Operating margin | โ | โ | โ6,492.7% | โ468.8% | โ1,097.6% | โ1,130.6% |
| EBITDA margin | โ | โ | โ6,445.8% | โ460.0% | โ1,082.6% | โ1,118.9% |
| Net margin | โ | โ | โ6,635.3% | โ722.1% | โ1,071.6% | โ1,115.3% |
| FCF margin | โ | โ | โ4,356.9% | โ497.6% | โ979.2% | โ960.1% |
| Returns | ||||||
| Return on capital employed | โ17.1% | โ106.8% | โ255.9% | โ53.3% | โ68.2% | โ34.9% |
| Return on equity | โ23.9% | โ100.7% | โ344.7% | โ294.0% | โ121.9% | โ68.5% |
| Return on assets | โ23.2% | โ73.8% | โ97.6% | โ74.6% | โ53.6% | โ43.3% |
| Return on tangible equity | โ23.9% | โ183.0% | โ17,493.6% | โ148.9% | โ124.8% | โ44.1% |
| Growth | ||||||
| Revenue growth | โ | โ | โ | 517.5% | โ46.1% | 17.3% |
| Share count change | โ | 113.1% | 16.7% | 164.2% | 115.4% | 27.8% |
| Financial health | ||||||
| Debt / equity | โ | 0.4x | 40.0x | 0.5x | 0.6x | 0.2x |
| Interest coverage | โ1,535.8x | โ121.3x | โ42.8x | โ14.5x | โ896.7x | โ1,753.9x |
| Current ratio | 36.2x | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Quick ratio | 36.2x | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Capital allocation | ||||||
| Capex / revenue | โ | โ | 824.1% | 25.0% | 4.5% | 7.6% |
| Stock comp / revenue | โ | โ | 721.1% | 51.2% | 157.2% | 136.1% |
| Quality scores | ||||||
| Piotroski F-score | โ | โ | 1.0 | 5.0 | 3.0 | 4.0 |
| Altman Z'' | 39.3 | โ4.9 | โ17.3 | โ7.4 | โ10.5 | โ0.5 |
| Accruals ratio | โ11.3% | โ24.3% | โ45.6% | โ25.8% | โ4.8% | โ6.3% |
Source: SEC EDGAR XBRL filings (CIK 0001806310). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.